Search    ENTER KEYWORD
MSDS Material Safety Data Sheet
CAS

44-20-8
6112-76-1

File Name: msds-gsk_com---1105730c.asp
SDS Number 110573            Approved/Revised 09-Aug-2006                                       Version 12
PURINETHOL TABLETS
Material



SAFETY DATA SHEET




1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
Material PURINETHOL TABLETS
PURI-NETHOL TABLETS * PURINETHOL TABLETS 25 MG * PURI-NETHOL
Synonyms
TABLETS 50 MG * MERCAPTOPURINA WELLCOME COMPRIMIDOS *
MERCAPTOPURINE MONOHYDRATE, FORMULATED PRODUCT
GlaxoSmithKline, Corporate Environment, Health & Safety
Company Name
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information: +44-20-8047-5000
Transport Emergency (EU) +44-1865-407333
Medical Emergency +1-612-221-3999, Ext 221
Information and Advice: US number, available 24 hours
Multi-language response

GlaxoSmithKline, Corporate Environment, Health & Safety
One Franklin Plaza, 200 N 16th Street
Philadelphia, PA 19102-1225 US
US General Information: +1-888-825-5249
Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response

2. COMPOSITION / INFORMATION ON INGREDIENTS
Percentage
Ingredients CAS RN
MERCAPTOPURINE MONOHYDRATE 16 to 40.3
6112-76-1
NON-HAZARDOUS INGREDIENTS 59.7 to 89.0
Unassigned

3. HAZARDS IDENTIFICATION
Expected to be non-combustible.
Fire and Explosion
Health Caution - Potent pharmaceutical agent.
Exposure might occur via ingestion; skin; eyes.
May cause cancer.
May produce adverse effects on human fertility.
May produce adverse effects on the development of human offspring.
Health effects information is based on hazards of components.
Environment No information is available about the potential of this product to produce
adverse environmental effects.

4. FIRST-AID MEASURES

Page 1 / 5
SDS Number 110573 Approved/Revised 09-Aug-2006 Version 12
PURINETHOL TABLETS
Material


Ingestion Never attempt to induce vomiting. Do not attempt to give any solid or liquid
by mouth if the exposed subject is unconscious or semi-conscious. Wash
out the mouth with water. If the exposed subject is fully conscious, give
plenty of water to drink. Obtain medical attention.
Inhalation Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact Using appropriate personal protective equipment, remove contaminated
clothing and flush exposed area with large amounts of water. Obtain
medical attention if skin reaction occurs, which may be immediate or
delayed.
Eye Contact Wash immediately with clean and gently flowing water. Continue for at least
15 minutes. Obtain medical attention.
NOTES TO HEALTH PROFESSIONALS
Medical Treatment Medical treatment in cases of overexposure should be treated as an
overdose of a cytotoxic agent. Treat according to locally accepted
protocols. For additional guidance, refer to the current prescribing
information or to the local poison control information centre.
Medical Conditions Refer to prescribing information for detailed description of medical
conditions caused by or aggravated by overexposure to this product.
Caused or Aggravated
by Exposure
Health Surveillance The need for pre-placement and periodic health surveillance must be
determined by risk assessment. Following assessment, if the risk of
Procedures
exposure is considered significant then exposed individuals should undergo
appropriate health surveillance that may include symptom enquiry, clinical
examination and monitoring of lead organ effects (e.g. full blood counts).
In the event of overexposure, individuals should receive post exposure
health surveillance focused on the most likely health effects (e.g. full blood
counts).
Antidotes No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES
Fire and Explosion Not expected for the product, although the packaging is combustible.
Hazards
Extinguishing Media Water, dry powder or foam extinguishers are recommended. Carbon
dioxide extinguishers may be ineffective.
Special Firefighting For single units (packages): No special requirements needed. For larger
amounts (multiple packages/pallets) of product: Since toxic, corrosive or
Procedures
flammable vapours might be evolved from fires involving this product and
associated packaging, self contained breathing apparatus and full protective
equipment are recommended for firefighters. If possible, contain and collect
firefighting water for later disposal.
Hazardous Combustion Toxic, corrosive or flammable thermal decomposition products are
expected when the product is exposed to fire.
Products
6. ACCIDENTAL RELEASE MEASURES
Personal Precautions Wear protective clothing and equipment consistent with the degree of
hazard. For all spills, isolate the spill area, restrict access, post the area for
a carcinogen and immediately implement emergency procedures for
cleanup and control of occupational carcinogens.
Environmental Precautions For large spills, take precautions to prevent entry into waterways, sewers, or
surface drainage systems.
Clean-up Methods Collect and place it in a suitable, properly labelled container for recovery or
disposal.


Page 2 / 5
SDS Number 110573 Approved/Revised 09-Aug-2006 Version 12
PURINETHOL TABLETS
Material


Decontamination No specific decontamination or detoxification procedures have been
identified for this product.
Procedures

7. HANDLING AND STORAGE
HANDLING
General Requirements Avoid breaking or crushing tablets.
STORAGE No storage requirements necessary for occupational hazards. Follow
product information storage instructions to maintain efficacy.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
MERCAPTOPURINE MONOHYDRATE
INGREDIENT
4
GSK Occupational
Hazard Category
REPRODUCTIVE HAZARD,
GSK Occupational 10 mcg/m3 (8 HR TWA)
CARCINOGEN
Exposure Limit
ENGINEERING CONTROLS
Containment Open handling may result in overexposure. Consider use of enclosures.
Administrative Strict control of access to the working area is essential. Restrict access to
authorised personnel.
* Other Equipment or Follow all local regulations if personal protective equipment (PPE) is used
in the workplace. Wear appropriate clothing to avoid skin contact. When
Procedures
isolation is not possible in production areas, appropriate personal protective
equipment must be used. Consider additional control procedures for
maintenance, cleaning and emergencies.

9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
Light yellow.
Colour
Tablet.
Physical Form

10. STABILITY AND REACTIVITY
Stability This product is expected to be stable.
Conditions to Avoid None for normal handling of this product.

11. TOXICOLOGICAL INFORMATION
Oral Toxicity Adverse effects might occur following ingestion.
Inhalation Toxicity No studies have been conducted.
Skin Effects Irritation is not expected following direct contact.
Eye Effects Irritation might occur following direct contact with eyes.
Target Organ Effects Adverse effects might occur in the following organ(s) following
overexposure: bone marrow and formation of blood cells; dividing cells;
gastro-intestinal tract; liver.
Sensitisation Sensitisation (allergic skin reaction) is not expected.
Genetic Toxicity Known or probable human mutagen.
Carcinogenicity Possible human carcinogen. (GSK). No components are listed as
carcinogens by IARC, NTP or US OSHA.



Page 3 / 5
SDS Number 110573 Approved/Revised 09-Aug-2006 Version 12
PURINETHOL TABLETS
Material


Reproductive Effects This material contains components which have been classified as: Known
or presumed to impair fertility in humans. Known or presumed to cause
toxicity in developing human offspring.
Pharmacological Effects This product contains active ingredient(s) with the following activity: a
cytotoxic agent.
Other Adverse Effects None known for occupational exposure.

12. ECOLOGICAL INFORMATION
Summary This material contains an active pharmaceutical ingredient that has been
tested and which may be harmful if released directly to the environment.
Appropriate precautions should be taken to limit release of this mixture to
the environment. Local regulations and procedures should be consulted
prior to environmental release.
ECOTOXICITY
Aquatic
Activated Sludge This material contains an active pharmaceutical ingredient that is not toxic
to activated sludge microorganisms.
Respiration
Daphnid This mixture contains an active pharmaceutical ingredient that is harmful to
daphnids.
MOBILITY
Solubility This mixture contains an active pharmaceutical ingredient that for
environmental fate predictions has limited solubility in water.
Partitioning This mixture contains an active pharmaceutical ingredient with
octanol/water partition coefficient data that suggests that for environmental
fate predictions the active pharmaceutical ingredient will not have the
tendency to distribute into fats.
PERSISTENCE/DEGRADATION
Biodegradation This mixture contains an active pharmaceutical ingredient that is not readily
nor inherently biodegradable (as defined by 1993 OECD Testing
Guidelines) and may persist in the environment.
13. DISPOSAL CONSIDERATIONS
Disposal Collect for recycling or recovery if possible. The disposal method for
rejected products/returned goods must ensure that they cannot be re-sold or
Recommendations
re-used. Wherever possible, disposal should be in an on-site licenced
chemical incinerator, if allowed by the incinerator licence or permit. If no
on-site incinerator is available, dispose of material in a licenced commercial
chemical incinerator.
Regulatory Requirements Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION
The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only
authorised persons trained and competent in accordance with appropriate national and international
regulatory requirements may prepare dangerous goods for transport.
UN Classification and Labelling
Transportation and shipping of this product is not restricted. It has no known,
Transport Information
significant hazards requiring special packaging or labelling for air, maritime, US
or European ground transport purposes.

15. REGULATORY INFORMATION


Page 4 / 5
SDS Number 110573 Approved/Revised 09-Aug-2006 Version 12
PURINETHOL TABLETS
Material


The information included below is an overview of the major regulatory requirements. It should not be
considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.
EU Classification and Labelling
Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal
product, cosmetic product or medical device.
US OSHA Standard (29 CFR Part 1910.1200)
* Classification This product is classified as hazardous according to the OSHA Hazard
Communication Standard. However, products that are subject to the
labelling requirements of the Food and Drug Administration are exempt
from the labelling provisions of the standard.
Target Organ May cause adverse effects on bone marrow; dividing cells; gastrointestinal
Statement tract; liver.
Other US Regulations
TSCA Status Exempt

16. OTHER INFORMATION
References GSK Hazard Determination
Date Approved/Revised 09-Aug-2006 SDS Version Number 12


SDS Sections Updated
Sections Subsections
EXPOSURE CONTROLS / PERSONAL PROTECTION Other Equipment or Procedures
IDENTIFICATION OF SUBSTANCE / PREPARATION AND
OF COMPANY
REGULATORY INFORMATION US Environmental (EPA) Requirements
US OSHA Standard (29 CFR Part 1910.1200) -
Classification
The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate
as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the
responsibility of the user to determine the applicability of this information and the suitability of the material
or product for any particular purpose.




Page 5 / 5

Search    ENTER KEYWORD
ALL Chemical Property And Toxicity Analysis PAGES IN THIS GROUP
NAMECAS
miraclesealants_com---s_seal_enhance_nonvoc.asp 64742-88-7
miracote_com---GLAZETOP_XT_III_COMP_A.asp 54914-37-3 2425-79-8 623-91-6 108-65-6
miracote_com---MVERS_II_Component_B_7255_10-25-07.asp 100-51-6 109-55-7 90-72-2
mnsu_edu---uni_ver-321.asp 497-19-8 14402-88-1 12125-02-9
mobilepropane_com---msds.asp 74-98-6 115-07-1 75-08-1
modernenvironmental_net---Oxine_MSDS.asp 7758-19-2 10049-04-4
molytec_com_au---MSDS_3660.asp 24448-20-2 3006-93-7 81-07-2 112945-52-5 80-15-9 27813-02-1 39382-25-7
monsterjanitorial_com---4772004.asp 98-86-2 77-83-8 628-63-7 100-52-7 140-11-4 91-64-5 141-78-6 64742-96-7
montereyagresources_com---ConditionXtra-0805-m.asp 7783-20-2 7664-38-2
montereyagresources_com---TechMaxGran-m.asp 10-27-6 10-38-2 10034-96-5
montereychemical_com---Moncide-m.asp 2163-80-6 124-65-2 75-60-5
montgomeryschoolsmd_org---Loctite_554.asp 25852-47-5 39382-25-7 80-15-9
mopbucketandwringer_com---2745097.asp 18472-51-0 106-47-8 56-55-1 67-63-0
mopbucketandwringer_com---3382080.asp 7732-18-5 151-21-3 68891-38-3 8051-30-7 61789-40-0 102-71-6 56-81-5 77-92-9 97-59-6 9016-45-9
mouldlife_co_uk---GB-EN-RENPIM_5216_POLYOL-164006700-MSDS.asp 105-59-9
mrcgene_com---msdsbcp.asp 109-70-6
mrdc_com---Copper_Nitrate_Soln._MSDS.asp 7732-18-5 23087-46-9
msds-1620.asp 147-85-3
msds-18037.asp 50-69-1
msds-19096.asp 3211-76-5 7757-93-9
msds-gsk_com---0021300b.asp 55011-47-0 44-20-8 103-90-2 125-69-9 345-78-8
msds-gsk_com---0022500a.asp 44-20-8 103-90-2 58-08-2
msds-gsk_com---0023420b.asp 44-20-8 103-90-2 41444-62-6 58-08-2
msds-gsk_com---0029150f.asp 55011-47-0 44-20-8 103-90-2 125-69-9 345-78-8 113-92-8
msds-gsk_com---0043490c.asp 44-20-8 103-90-2 61-76-7 50-81-7
msds-gsk_com---11056509.asp 44-20-8 20830-75-5
msds-gsk_com---1105690d.asp 44-20-8 55-98-1
msds-gsk_com---1105730c.asp 44-20-8 6112-76-1
msds-gsk_com---1105790a.asp 44-20-8 154-42-7
msds-gsk_com---12346704.asp 44-20-8 126-07-8
msds-gsk_com---12729505.asp 44-20-8 20830-75-5 64-17-5
msds-gsk_com---12746807.asp 44-20-8 67-97-0 59-02-9
msds-gsk_com---12773005.asp 44-20-8 8007-45-2 97-59-6 50-23-7
msds-gsk_com---12792505.asp 44-20-8 103-90-2 93-14-1 61-76-7
msds-gsk_com---12946804.asp 44-20-8 103-90-2 61-76-7
msds-gsk_com---12973801.asp 44-20-8 103-90-2 93-14-1 61-76-7 64-17-5
MSDS_2220-VF_US_11May07.asp 50-01-1 79-14-1 56-81-5 4998-76-9
MSDS_2222-VF_US_03Jul03.asp 107-41-5 57-13-6
MSDS_2331_US_16Aug06.asp 67-63-0 56-81-5 506-59-2 111-41-1 64-19-7 79-14-1 9036-19-5
MSDS_5744_UK_04Jun03.asp 13826-83-0 14075-53-7
MSDS_7210_US_15Mar05.asp 111-76-2 126-86-3
msds_anhrefractories_com---ISO-STAR_MX_USA.asp 1344-28-1 1309-48-4 9003-35-4 7782-42-5 7440-21-3 1333-86-4 4067-16-7
msds_anhrefractories_com---NARTAR_7_USA.asp 1309-48-4 68187-58-6 10124-37-5
msds_anhrefractories_com---PLASTECH_90P_STDUSA.asp 1344-28-1 14335-33-2 1302-78-9 13530-50-2 14808-60-7
msds_anhrefractories_com---UNACAST_30-90_TI_USA.asp 1309-48-4 68187-58-6 10361-03-2
msds_anhrefractories_com---UNACAST_HPU_TI.asp 1344-28-1 68187-58-6 12042-68-1 471-34-1 546-93-0
msds_anhrefractories_com---WO-6878_BATCH_USA.asp 1309-48-4 7782-42-5 7429-90-5 9003-35-4 7440-21-3 4067-16-7
msds_carboline_com---0481a1nl_2_usansi.asp 25036-25-3 540-88-5 108-88-3 25068-38-6 392662-40-7 71-36-3 75-65-0
msds_carboline_com---0497c1nl_2_usansi.asp 108-88-3 67-63-0 392662-40-7 100-51-6 9046-10-0 694-83-7 90-72-2 108-38-3 100-41-4
msds_carboline_com---8222s1nl_2_usansi.asp 014807-96-6 111-76-2 5131-66-8 78-92-2 88-12-0

Free MSDS Search ( Providing 250,000+ Material Properties )
Chemcas.com | Ads link:HBCCHEM.INC